Bioventus Inc.
BVS
$8.60
$0.091.06%
NASDAQ
| 03/28/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -16.35% | 13.88% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -16.35% | 13.88% | |||
| Cost of Revenue | -15.88% | 10.57% | |||
| Gross Profit | -16.56% | 15.44% | |||
| SG&A Expenses | -5.38% | 5.23% | |||
| Depreciation & Amortization | -14.65% | -7.22% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.53% | 6.90% | |||
| Operating Income | -59.08% | 92.83% | |||
| Income Before Tax | -68.06% | 202.85% | |||
| Income Tax Expenses | 117.98% | -578.16% | |||
| Earnings from Continuing Operations | -77.21% | 332.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 67.50% | -201.18% | |||
| Net Income | -78.90% | 367.67% | |||
| EBIT | -59.08% | 92.83% | |||
| EBITDA | -25.71% | 19.32% | |||
| EPS Basic | -78.97% | 367.52% | |||
| Normalized Basic EPS | -70.31% | 235.78% | |||
| EPS Diluted | -80.88% | 344.16% | |||
| Normalized Diluted EPS | -70.58% | 234.74% | |||
| Average Basic Shares Outstanding | 0.41% | 0.14% | |||
| Average Diluted Shares Outstanding | 1.08% | 0.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||